A PHASE 1B SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY OF VERVE-201 IN PATIENTS WITH REFRACTORY HYPERLIPIDEMIA

Registry ID

VT-20101

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

VERVE THERAPEUTICS, INC., A WHOLLY OWNED SUBSIDIARY OF ELI LILLY AND COMPANY

Start date

2025-09-12

Last update

2024-08-21

Conditions

• HYPERLIPIDEMIA

Related clinical trials

• PHASE 1/2A, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF ARO-DIMERPA IN ADULT SUBJECTS WITH MIXED HYPERLIPIDEMIA
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENLICITIDE DECANOATE COADMINISTERED WITH ROSUVASTATIN IN ADULTS WITH HYPERLIPIDEMIA
• A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFECT OF AZD0780 ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR AT RISK FOR A FIRST ATHEROSCLEROTIC CARDIOVASCULAR DISEASE EVENT
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BEMPEDOIC ACID (ETC-1002) 180 MG/DAY AS ADD-ON TO EZETIMIBE THERAPY IN PATIENTS WITH ELEVATED LDL-C
• A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY ON LDL-C OF EVOLOCUMAB (AMG 145) IN SUBJECTS WITH HIV AND WITH HYPERLIPIDEMIA AND/OR MIXED DYSLIPIDEMIN
• A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF EVOLOCUMAB (AMG 145) IN COMBINATION WITH STATIN THERAPY IN DIABETIC SUBJECTS WITH HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

View on source registry